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The major goal in vaccination is establishment of long-term, prophylactic humoral mem-
ory to a pathogen.Two major components to long-lived humoral memory are plasma cells
for the production of speciﬁc immunoglobulin and memory B cells that survey for their
speciﬁc antigen in the periphery for later afﬁnity maturation, proliferation, and differenti-
ation. The study of human B cell memory has been aided by the discovery of a general
marker for B cell memory, expression of CD27; however, new data suggests the exis-
tence of CD27− memory B cells as well. These recently described non-canonical memory
populations have increasingly pointed to the heterogeneity of the memory compartment.
The novel B memory subsets in humans appear to have unique origins, localization, and
functions compared to what was considered to be a “classical” memory B cell. In this
article, we review the known B cell memory subsets, the establishment of B cell memory
in vaccination and infection, and how understanding these newly described subsets can
inform vaccine design and disease treatment.
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INTRODUCTION
THE DISCOVERY OF IMMUNOLOGICAL MEMORY
Immunological memory as a biological phenomenon has its roots
in a simple, but powerful, observation; exempliﬁed by Thucydides
during an outbreak of the plague in Athens during the summer of
430 BC, “Yet it was with those who had recovered from the dis-
ease that the sick and the dying found most compassion. These
knew what it was from experience, and had now no fear for them-
selves; for the same man was never attacked twice – never at least
fatally” (Thucydides et al., 1996). This observation was utilized
in the vaccination experiments much later by Edward Jenner and
Louis Pasteur. Jenner being the ﬁrst to realize in Western soci-
ety that people could be protected against the disease smallpox
by immunizing the individual ﬁrst with the avirulent cowpox;
the term “vaccine” derives its name from the Vaccinia virus of
smallpox (Morgan and Parker, 2007). Pasteur took these obser-
vations a step further during his famous cholera experiments in
chickens; where he discovered that components of the pathogen,
derived in a laboratory setting, could be used to create a protective
immune response (Pasteur, 1881a,b). Essentially, with the correct
material, any disease had the potential to be vaccinated against
without having to ﬁnd an avirulent relative in nature (Pasteur,
1881a,b).
Pasteur and Jenner had stumbled upon one of the most
advantageous traits of the vertebrate adaptive immune system,
immunologicalmemory,and through their studies theydiscovered
how to purposefully unlock the phenomena. It was this princi-
pal that allowed vaccinology to ﬂourish; dampening or outright
eliminating major disease threats that have plagued our species
throughout recorded history.
GENERATION OF MEMORY
The major goal of the adaptive immune system after every infec-
tion is to remember the insult and provide proper, effective pro-
tection upon secondary challenge by the same pathogen; in doing
so, usually preventing the symptoms of the disease. Most vaccines
are designed to protect against pathogens by generating humoral
immune responses, which prevent the entry and establishment of
an infection (Ahmed et al., 2007). In order to create usefulmemory
to an immunological insult the body requires both T and B cells;
the primary focus of this review will be the B cell compartment.
Humoral immunity is initiated from naïve B cells in the periph-
eral blood that enter lymph nodes through the lymphatic system.
Upon entering the lymph node, these B cells have the ability to
sample antigen presented on subcapsularmacrophages in the form
of immune complexes and later interact with networks of follicu-
lar dendritic cells (FDCs) during a germinal center (GC) reaction
(Szakal et al., 1988; Junt et al., 2007; Phan et al., 2009). If a B cell is
able to bind antigen through its B cell receptor (BCR), it will inter-
nalize the complex and present the processed antigen on major
histo-compatibility complex class II (MHC class II) molecules to
CD4+ T cells at the T–B boarder (Lanzavecchia, 1990; Van Kooten
and Banchereau, 2000, #3189; Okada et al., 2005). Later on in the
response this help will be provided by a subpopulation of T cells
that localize to GCs known as T Follicular Helper cells (TFH cells;
Lanzavecchia, 1990; Van Kooten and Banchereau, 2000; Haynes
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et al., 2007). The B cells will then be informed that they bind to an
immunologically relevant antigen through T cell receptor (TCR)–
MHC class II and CD40–CD40L interactions (Banchereau and
Rousset, 1991; Jaiswal and Croft, 1997). This interaction informs
the B cell to enter a GC reaction (Liu et al., 1991b). In such a state
B cells begin to rapidly divide as centroblasts in the dark zone of
the GC (Liu et al., 1991b). The activation of one of these cells
by this cognate ligand allows for a massive proliferative response
ﬁrst postulated by Burnet (1957) and Talmage (1957) in their
theory of clonal selection. As they divide, the cells mutate their
Immunoglobulin (Ig) genes through the process known as somatic
hypermutation (SHM; Weigert et al., 1970). SHM is controlled
through the expression of the enzyme activation-induced cytidine
deaminase (AID; Muramatsu et al., 2000; Revy et al., 2000). This
enzyme also allows for class-switch recombination (CSR),which is
the exchange of the heavy chain constant (C) regions of antibod-
ies to different C regions down the Ig locus (Kincade et al., 1970).
The isotype that is produced in the B cell will depend greatly on
the cytokine milieu experienced by the B cell (Snapper and Paul,
1987). CSR will alter the effector function of the antibody but
not its speciﬁcity. After rounds of rapid division and mutation,
B cells emerge from the GC to test their altered BCR’s speciﬁcity
against the antigen presented on FDCs (Nieuwenhuis and Opstel-
ten, 1984; Victora et al., 2010). Again they attempt to acquire T
cell help, occurring in the light zone of the GC as centrocytes;
if the B cell was successful in acquiring antigen, it will again be
able to obtain T cell help through MHC class II–TCR interactions
(Victora et al., 2010). If this interaction is unsuccessful, the B cell
will die by apoptosis (Liu et al., 1989). However, if the B cell is
able to get help, it will upregulate the survival markers, such as
Bcl2, and graduate that round of GC selection; allowing it to again
enter for another round (Liu et al., 1991a). This process is known
as afﬁnity maturation. Eventually, antigen will become limiting as
the immune response wanes; leading to only the highest afﬁnity
BCRs being able to compete for antigen and acquire the crucial
T cell help (Schwickert et al., 2011). These cells can exit the GC
reaction as either antibody secreting cells (ASCs), such as plas-
mablasts and long-lived plasma cells, or they can leave as memory
B cells, which then take up residence in tissue and circulate in the
peripheral blood to survey for their antigen (Arpin et al., 1995).
Memory B cells can be stimulated later on by means of spe-
ciﬁc interaction with their antigen or by polyclonal stimulation;
resulting in the creation of plasmablasts and plasma cells that can
produce a high afﬁnity, speciﬁc antigen response (Bernasconi et al.,
2002). This idea however, has been challenged by human ﬁnd-
ings that have shown no serum level changes in antibodies to
a panel of vaccinating antigens when individuals are stimulated
with boosters or experience infection reactivation with exception
to the response to the recent antigen of challenge (Amanna et al.,
2007, #5460). Importantly, these cells are able to respond to their
antigen of interest faster than naïve B cells by not requiring cognate
T cell help for activation through the receptor-intrinsic costimula-
tion created following class-switch (Klinman and Doughty, 1973;
Liu et al., 1995; Hebeis et al., 2004; Engels et al., 2009). Interest-
ingly, there appears to be an intricate orchestration of the memory
response; most recently demonstrated in mouse models. GC reac-
tions can produce both long-lived, somatically mutated IgM, and
isotype-switched memory B cells (Dogan et al., 2009; Pape et al.,
2011). Somaticallymutated IgM+ B cells appear to be the predom-
inate population in the revival of GCs during secondary responses,
while isotype-switched memory B cells engaged in effector func-
tions against the insult; promoting the idea that each isotype may
have a speciﬁc role during amemory response to pathogen (Dogan
et al., 2009; Pape et al., 2011). Collectively, these properties of the
memory B cell compartment allow for a more potent response
following secondary exposure to the cognate antigen.
For the purposes of this review, we will deﬁne memory B cells
as B cells that are long-lived, antigen experienced, transferrable to
non-immune host, and quiescent cells that require reactivation.
This last criterion helps to distinguish these cells from terminally
differentiated plasma cells that are always active and producing Ig.
While the deﬁnition of what constitutes a memory cell is relatively
simple to derive in theory; actually characterizing a population of
cells that are bona-ﬁde memory cells by this deﬁnition has taken
signiﬁcant effort and will be the primary focus of this review.
The generation of memory responses is critical for the effective
response to a vaccine and invading pathogens. These responses
do not produce a homogenous population of memory cells but
a constellation of subsets depending on the kinetic time point,
location, and type of infection or vaccination. It has been in
these contexts that a large number of memory cell subsets have
been observed. Understanding these subsets will be paramount in
the creation of novel, effective vaccines to pathogens that do not
lend themselves easily to vaccination. In this review, we discuss
the distinct subsets of B cells that comprise the larger popula-
tion of “memory B cells” in humans. It is hoped that by better
understanding these memory B cell subsets, treatments can be
devised to take advantage or avoid the formation of these varied
compartments.
THE DISCOVERY OF CD27
Before the advent of CD27 as a general marker for human memory
B cells, expression of several different markers was relied upon to
parse out memory populations. Expression of the immunoglob-
ulin isotype IgD was typically used as a means of removing naïve
B cells populations; as was the marker CD38 to distinguish GC
B cells (Liu et al., 1989; Pascual et al., 1994). To survey positively
for memory cells, expression of IgG and IgA could be assayed as
evidence of antigen experience and isotype switch (Moller and
Wigzell, 1965; Bourgois et al., 1977). This roundabout method
for identifying memory cells would make comparative analysis of
memory populations more difﬁcult; which has been a major pit-
fall in mouse models for many years, due to the lack of a unifying
memory B cell marker.
Maurer et al. (1990) discovered a population of B cells express-
ing a previously known T cell marker, CD27 (Black et al., 1978;
Eisenbarth et al., 1980). Importantly, the population of CD27+ B
cells discovered were in high prevalence in adult peripheral blood
but not present in fetal cord blood (Maurer et al., 1990). These
CD27+ B cells also expressed IgM and IgD at signiﬁcantly lower
frequencies than CD27− B cells as well as secreted IgG and IgM
in higher titer following stimulation, leading the authors to spec-
ulate that these cells were “pre-activated” (Maurer et al., 1990,
1992). CD27 is a TNF family member receptor whose ligand,
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CD70 or CD27L, is expressed on activated T and B cells (Bowman
et al., 1994). Importantly, CD27–CD70 interaction has been seen
to induce ASC development and antibody secretion (Agematsu
et al., 1995, 1997, 1998a). Further analysis of the B cell popula-
tions expressing CD27 revealed a unique morphology, containing
a larger amount of cytoplasm than CD27− populations; lending
further evidence that these cells were previously activated lympho-
cytes (Agematsu et al., 1997). Finally, in 1998, two back-to-back
publications showed that these CD27+ cells were antigenically
experienced in contrast with their CD27− counterparts due to the
increased load of somatic mutations in the variable genes of the
CD27+ compartment of B cells; this effect being seen in both the
peripheral blood and the splenic tissue, but absent in CD27− frac-
tion of lymphocytes (Klein et al., 1998b; Tangye et al., 1998). This
discovery, combined with previous ﬁndings, gave weight to the
claim that this marker was a characteristic shared by all memory
B cells. Notably, although not often used, the Tangye et al. (1998)
report also found that memory cells express CD148. Interestingly,
CD27 expression is not exclusive to memory B cells as ASCs also
have high CD27 expression on their surface, these two populations
can easily be differentiated through the presence of other markers
such as CD38 and CD20 (Brokstad et al., 1995; Bernasconi et al.,
2002; Wrammert et al., 2008a; Smith et al., 2009).
By deﬁning a general marker for memory B cells in humans,
more in-depth analysis of the phenotypes of memory populations
has been made possible. However, as will be described later, CD27
has been more recently realized to be unable to fully characterize
all memory B cell subsets, as several new populations have been
discovered that have fallen outside the detection of this broad
marker.
DIFFERENT SUBSETS
Since the deﬁnition of memory B cells in humans by CD27 expres-
sion, the capacity to discriminate B memory subsets has increased
exponentially. Outside the discovery of a heterogeneous popu-
lation of B cell memory subsets, questions remain concerning
the generation and the function of many. We begin by describ-
ing the currently known subsets of human memory B cells. See
Box 1.
CD27+ SWITCHED MEMORY CELLS (IgG+/IgA+/IgE+)
Memory B cells in human have been originally described as
IgD−CD27+ cells, which have undergone the CSR and SHM
process, in comparison to IgM+IgD+CD27− naïve B cells. These
“classical” memory cells express IgG, IgA, or IgE and they derive
from T cell-dependent (TD) response in the GC (Pascual et al.,
1994). As discussed below, IgM+CD27+ cells are also memory
subsets, but may have roles differing from the class-switched pop-
ulations. The general function of these cells is to induce a rapid
and robust response after re-exposure to a pathogen or antigen by
the differentiation to high afﬁnity plasma cells (Arpin et al., 1995).
These cells recirculate in the peripheral blood, spleen, and tissues
to survey for their cognate antigen (Klein et al., 1998b; Tangye
et al., 1998; Montoya et al., 1999). It is interesting to consider that
the various secondary, class-switched isotypes of Ig may represent
a population multiplier. Clearly, the various isotypes utilize differ-
ent intracellular domains as BCRs and are associated with speciﬁc
functional roles such that an IgA “mucosal memory” cell may be
quite distinct functionally from IgG1 or IgG4 expressing memory
cells.
TISSUE-SPECIFIC AND “TISSUE-LIKE” MEMORY: CD27−FCRL4+
MEMORY CELLS
The advent of CD27 as a general memory marker allowed great
strides in the study of the memory compartments of human B
cells. It came as a great surprise when B cell subsets that appeared
to be newly discovered members of the memory compartment
were located but lacked the expression of CD27.
Box 1 | Known B cell memory subsets.
CD27+ memory cells CD27− memory cells
Switched IgG+/
IgA+/IgE+
Switched
IgD+IgM−
IgM memory FCRL4+ IgG+ IgA+
IgM-only IgM+IgD+
Origin Late GC Late GC Early GC Early GC
GC-independent
Not known Early GC GC-
independent
Tissue
distribution
Second
lymphoid, PB
Mucosal tissue,
PB
Second
lymphoid, PB
Second lymphoid
(MZ of spleen),
PB
MALT Second
lymphoid, PB
PB, gut?
Function TD response TD/TI response TD response? TI response Not known TD
response?
TI response?
TI response? Basophil
activation
TD response?
Transcription
factor
RUNX1 Not known Not known Notch2? RUNX2, SOX5 RUNX1? Not known
% of PB B
cells
11–17 1–3 5 15 <0.2% in PB
(9.5% in
tonsil)
1–4 4
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In 2003, work was being done to characterize a new set of
B cell inhibitory receptor genes, known as the Ig superfamily
receptor translocation associated genes (IRTA; Miller et al., 2002;
Falini et al., 2003). The gene IRTA1, encoding the orphan receptor
Fc-receptor-like-4 (FCRL4) molecule, was present on mucosally
associated B cells and contained several immunoreceptor tyrosine-
based inhibitory motifs (ITIMs); these were later shown to be
potent negative regulators of BCR signaling (Miller et al., 2002;
Ehrhardt et al., 2003; Falini et al., 2003). The inhibitory function
of FCRL4 in B cells was seen to be mediated by the protein SHP-1
(Ehrhardt et al., 2003).
When this population was later located in the tonsillar tissue
of humans, it was found that the cells did not express the mem-
ory marker CD27 (Ehrhardt et al., 2005). This B cell population
was not seen in the blood, spleen, or bone marrow of human
patients (Miller et al., 2002; Ehrhardt et al., 2005). However, these
tissue localized B cells did have evidence of SHM, CSR to IgG
and IgA, and lacked expression of GC markers (Ehrhardt et al.,
2005). These cells also carried conventional markers of activa-
tion as well as higher CD20 expression (Ehrhardt et al., 2005).
Interestingly, these CD27−FCRL4+ B cells were larger than their
CD27+FCRL4− counterparts and could be stimulated to secrete
Ig using T cell cytokines but not BCR stimulation (Ehrhardt et al.,
2005). A gene array analysis of FCRL4+ versus FCRL4− cells from
tonsillar tissues has revealed that these cells differ in their tran-
scriptome proﬁles. Expression of the transcription factors RUNX1
and RUNX2 appears to be a major difference between these pop-
ulations (Ehrhardt et al., 2008). Moreover, the FCRL4+ memory
B cells have a distinct expression patterns for receptors, signal
transduction molecules, and transcription factors (Ehrhardt et al.,
2008). The function of these cells is not deﬁned but they may be
important in the mucosal immune response. The discovery of a
new subset of tissue-speciﬁc memory B cells that were not identi-
ﬁable by CD27 staining spurred the notion that the B cell memory
compartment was much more intricate than initially assumed.
Recent work done in the surveying of B cell responses to
HIV has revealed a population of B cells in the peripheral blood
that appeared to share a similar phenotype to tissue-speciﬁc
CD27−FCRL4+ B cells described in tonsillar tissues (Ehrhardt
et al., 2005; Moir et al., 2008). Interestingly, these HIV-infected
viremic patients were seen to have this CD27−FCRL4+ popula-
tion present in their peripheral blood at a frequency of 19% of
total B cells, which is in stark contrast to the <4% of the same
population in healthy individuals (Moir et al., 2008). This cell
population, deemed“tissue-like memory B cells,” expressed mark-
ers of past SHM, albeit at a lower frequency and diversity than
normal CD27+ memory cells, and showed a reduced tendency
to proliferate in response to cognate antigen (Moir et al., 2008).
These tissue-like memory B cells also expressed not only FCRL4,
but a number of other inhibitory receptors and chemokine recep-
tors that would reduce the likelihood of B–T cell interaction (Moir
et al., 2008). Further, these tissue-like memory B cells had reduced
capability to produce ASCs but were the cell population most spe-
ciﬁc for the HIV gp120 protein (Moir et al., 2008). Speciﬁc siRNA
knockdown of FCRL4 and other inhibitory receptors led to a res-
cue of Ig secretion and proliferation in these tissue-like memory
B cells (Kardava et al., 2011). This phenotype resembled what had
been seen in exhausted CD8+ T cells (Day et al., 2006), giving
credence to the idea that this was an “exhausted” memory B cell
population (Moir et al., 2008).
Since the identiﬁcation of an exhausted population of B cells,
similar phenotypes have been witnessed in other chronic diseases
such as malaria and hepatitis-C (Weiss et al., 2009; Charles et al.,
2011). It would appear that chronic infections have means to alter
human B cell populations to their own beneﬁt; overstimulation
of B cells can be quite deleterious to the host and needs to be
properly regulated. Vaccines that safely overcome this exhaustion
phenotype may be necessary in order to develop proper immunity
to these chronic, dangerous diseases.
CD27+ IgD+IgM− MEMORY CELLS
Naïve B cells typically express both IgM and IgD isotypes on
their surface, the differential production of these two antibody
isotypes is controlled by alternative splicing of the immunoglob-
ulin heavy chain RNA transcripts (Early et al., 1980; Moore et al.,
1981; Kinashi et al., 1987). Interestingly, there is a population of
antigen experienced human CD27+IgD+IgM−, “IgD only,”mem-
ory B cells in the blood and a IgD+IgM− plasma cell population
that reside speciﬁcally in respiratory mucosal linings of humans
(Liu et al., 1996; Arpin et al., 1998; Klein et al., 1998a).
These cells were initially discovered in 1989 during investi-
gations of human myeloma patients (Yasui et al., 1989; White
et al., 1990). These IgD+IgM−CD27+ memory B cells or “Cδ
class-switched” cells are the product of a class-switch event at
the Cμ and cryptic Cδ switch recombination regions of the Ig
heavy chain or, interestingly, by a separate non-classical homolo-
gous recombination event (Yasui et al., 1989; White et al., 1990).
IgD+IgM− B cells carry some of the largest SHM burdens seen
to date in their Ig genes; along with having a large skewing for
use of lambda light chains (Arpin et al., 1998; Klein et al., 1998a;
Zheng et al., 2004) as well as highly restricted VH gene reper-
toires (Wilson et al., 2000; Zheng et al., 2004; Koelsch et al., 2007;
Seifert et al., 2009), with 50–60% of the BCRs being encoded by
one of only two heavy chains; VH3–30 or VH4–34. VH4–34 has
long been associated with B cell autoimmunity (Pascual et al.,
1991, 1992; Pugh-Bernard et al., 2001). This plus high levels of
receptor editing for both the heavy and light chain loci, combined
with higher auto- and poly-reactivity scoring in healthy individ-
uals have implicated these cells in being uniquely selected during
B cell development and immune responses (Wilson et al., 2000;
Zheng et al., 2004; Koelsch et al., 2007). B1 and marginal zone
cells in mice also express poly-reactive prone BCRs from a highly
restricted BCR repertoire (Kearney, 2005), thus one can postulate
that like these populations, IgD+IgM−CD27+ might serve more
specialized innate-like or tissue-speciﬁc roles.
More recently work has been performed on possible effector
functions of IgD+IgM− B cells that supports the possibility that
these cells are to some degree functional analogs to B1 or MZ
cells. Plasmablasts from human samples were seen to develop in
the respiratory mucosa and produce IgD that was speciﬁc for
pathogens of the respiratory tract (Chen et al., 2009). Interest-
ingly, the IgD that was produced was seen to bind strongly to
the Fc receptors on the surface of basophils (Chen et al., 2009).
This crosslinking of IgD on the surface of basophils lead to the
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release of B cell-activating factors and antimicrobial compounds
(Chen et al., 2009). The authors concluded that these IgD+IgM−
plasma cells and IgD+IgM−CD27+ memory cells appear to play
an important role in respiratory mucosal defense via the activation
of basophil populations; providing at least one possible function
for this mysterious cell population in vivo (Chen et al., 2009).
CD27−IgG+ AND CD27−IgA+ MEMORY CELLS
Further heterogeneity in memory B cell subsets has been reported
with CD27−IgG+ B cells that exhibit classic attributes of mem-
ory cells, including SHM and expression of co-stimulatory mol-
ecules (Fecteau et al., 2006; Wei et al., 2007). CD27−IgG+
and CD27+IgG+ memory B cells differed in the distribution
of IgG subclasses, with a predominance of IgG2 expression in
CD27+IgG+, while CD27−IgG+ expressed preferentially IgG3
(Fecteau et al., 2006). In humans, IgG2 antibodies are mainly
reactive to polysaccharides while IgG3 antibodies more often react
with proteins; the unique isotype distributions between these two
populations further suggests that CD27−IgG+ B cells could be dis-
tinct in their function (Fecteau et al., 2006). Moreover, analysis by
Berkowska et al. (2011)has led to the conclusions thatCD27−IgG+
cells are derived from early GC reactions, like IgM-only mem-
ory cells described below, whereas CD27+IgG+ cells are derived
from consecutive GC reactions based on the replication history,
SHM, and CSR data of these two populations. Interestingly, these
CD27−IgG+ cells are expanded in SLE patients compared with
healthy controls (Wei et al., 2007). It is not yet known how these
cells effect disease progression.
A minor population of memory cells have been described as
CD27−IgA+. These cells have fewer mutations than CD27+IgA+
cells and they may originate from local GC-independent responses
in the gut, such as IgA+ Bcells from the lamina propria (Berkowska
et al., 2011). The function of this population remains to be studied.
Both CD27−IgA+ and CD27−IgG+ populations are increased
in patients with HIV chronic infection and an increased IgA pro-
duction by CD27−IgA+ cells was observed upon CD40 and TLR9
stimulation in vitro (Cagigi et al., 2009). These CD27− isotype-
switched memory cells (IgG+ and IgA+) can be discriminated
from CD27− naïve cells by the absence of ATP-binding cassette B1
transporter (ABCB1) activity (Wirths and Lanzavecchia, 2005).
Therefore, CD27– memory cells, in opposition to CD27+ mem-
ory cells, are essentially disconnected from any further regulation
through CD70, the ligand of CD27, supporting once more their
distinct roles in immune responses (Fecteau et al., 2006).
The diversity of memory B cells may reﬂect the different origins
and nature of the encounter antigens; leading to different possible
functions of these memory B cells. The real contribution of each
subset in the immune response should be the aimof future studies.
CD27+IgM+IgD+ AND CD27+IgM+IgD− MEMORY B CELLS
In the late 1990s, studies reporting a large proportion of CD27+
B cells that have undergone SHM, but not Ig isotype switch-
ing, provided support for the existence of IgM+ memory B
cells (Klein et al., 1997; Tangye et al., 1998). Further investi-
gations led to the subdivision of this population by describing
the CD27+IgM+IgD− (IgM-only) and CD27+IgM+IgD+ subsets
(Klein et al., 1997, 1998a; Weller et al., 2001). A recent study based
on the analysis of replication history, SHM, and CSR has shown
that IgM-only B cells derive from early GC reactions, whereas
CD27+IgM+IgD+ memory B cells have in part a GC-independent
origin (Berkowska et al., 2011).
It has been observed that CD27+IgM+IgD+ B cells correspond
to splenic marginal zone B cells by CDR3 spectratyping and gene-
expression proﬁle analysis (Weller et al., 2004). Developmental
diversiﬁcation of these cells has been demonstrated in environ-
ments lackingGCs,T-dependent (TD) antigen response, and prior
to T-independent (TI) pathway in young children (Weller et al.,
2008). These somatically mutated CD27+IgM+IgD+ B cells are
present in patients that lack GC formation due to CD40 or CD40L
deﬁciency,meaning classical isotype-switched and IgM-only B cell
populations are absent (Agematsu et al., 1998b;Weller et al., 2001).
Functionally,CD27+IgM+IgD+ memory cells appear toplay a role
in response to TI antigens, most notably the response to encapsu-
lated bacteria. However, they do seem to maintain the capacity to
participate in TD responses (Kruetzmann et al., 2003;Weller et al.,
2004).
IgM+ MEMORY CELLS
T-DEPENDENT VERSUS T-INDEPENDENT MEMORY
Classically it has been thought that memory B cells are generated
in GC in response to TD antigens. Within the GC, the antigen-
speciﬁc cells are selected and undergo SHM to improve the afﬁnity
for antigen. TD antigens are classically proteins and the T cell
help is necessary to elicit an antibody response (Vallé et al., 1989;
Agematsu et al., 1995). In contrast, T-independent (TI) antigens,
such as polysaccharides, can elicit a response without T cell help.
The concept of TI B cell memory has been counter to B cell
memory dogma for a long time. Initially, it was assumed that TI
antigens do not elicit an ampliﬁed and afﬁnity-matured antibody
response upon secondary immunization (Defrance et al., 2011).
However, recent studies in mice demonstrated TI memory as long-
lived, anti-bacterial humoral immunity by adoptive transfer of B
cells from mice that had cleared a B. hermsii infection into naïve
recipients (Alugupalli et al., 2004). The analysis of mouse B cell
populations showed that B1-b cells are the source of the memory
cells (Alugupalli et al., 2004). The existence of TI memory cells
has also been conﬁrmed with the presence of a pool of quiescent,
antigen-speciﬁc B cells 120 days after immunization (Obukhanych
and Nussenzweig, 2006).
HUMAN B1 CELL POPULATIONS
In mice, B cells are divided into B1 cells (B1-a and B1-b) and
B2 cells (follicular cells and marginal zone cells). B1 and mar-
ginal zone (MZ) B cells are innate-like B cells that secrete natural
antibodies rapidly in response to infections or tissue injury. The
development of B1 cells and their response patterns against anti-
gen have been recently reviewed by Baumgarth (2011). Differences
in responses to pathogens between the two related populations
reside mainly in the BCR activation. Indeed, in response to vari-
ous stimuli (S. pneumonia, certain carbohydrates, LPS, and certain
cytokines) bothB1-a andB1-b cells respondwith secretionof poly-
reactive IgM antibodies (IgA is also possible in the gut), a low level
of cell proliferation, and no apparent BCR signaling (Nisitani et al.,
1995;Ohdan et al., 2000;Martin et al., 2001). In contrast, following
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repeated exposure to TI antigens, only B1-b cells can expand clon-
ally, driven by BCR signaling, and secrete antigen-speciﬁc IgM
antibodies as a memory response (Defrance et al., 2011).
The existence of B1 cells in humans is controversial; vari-
ous studies have provided evidence of populations that appear
to be similar to the mouse B1 phenotypes, but B1-a and B1-
b populations per se still lack deﬁnition (Grifﬁn et al., 2011).
However, polysaccharide vaccines (TI antigens), such as Pneu-
movax, confer long-term humoral protection in adult humans,
suggesting possible TI memory in humans (Lesinski and West-
erink,2001).Notably,however,unlike the antibody genes of typical
T-independent responses in mice, the Pneumovax vaccine induces
B cells with highly mutated variable genes, similar to T cell depen-
dent responses (Smith et al., 2009). However, it is impossible to
say by this study alone whether these cells obtained their somatic
mutations solely through the interaction with the TI antigen alone
or whether the cells that were stimulated arose from an already
somatically mutated TD memory population; more work must be
done here to deﬁnitively resolve this issue. There is still consider-
able debate concerning the function of IgM+ memory B cells as
human B1 cells. However, there is evidence that IgM+ memory B
cells are implicated in response to bothTI andTDantigens (Tangye
and Good, 2007). It is important to note that the recently realized
heterogeneity of this population may explain the complexity in
their function.
THE DUAL ROLE OF IgM+ MEMORY CELLS: T-INDEPENDENT AND
T-DEPENDENT RESPONSES
We will be deﬁning IgM+ memory cells as CD27+IgM+IgD± as
most of the studies do not make the distinction between IgD
expression of IgM+ memory B cells. These cells, as mentioned
earlier, are implicated primarily in TI responses. First, evidence
for human IgM+ memory B cells being involved in TI responses is
best observed in immunocompromised individuals. IgM+ mem-
ory cells are reduced in asplenic patients and it is known that these
individuals are highly susceptible to infection with encapsulated
bacteria (Zandvoort and Timens, 2002; Kruetzmann et al., 2003).
A similar phenomenon is also seen in both common variable
immunodeﬁciency (CVID) and elderly patients that lack IgM+
memory cells (Carsetti et al., 2005; Shi et al., 2005). Importantly,
in all these cases the susceptibility to encapsulated bacterial infec-
tionswas heavily dependent on the presence of IgM+ memory cells
(Kruetzmann et al., 2003; Carsetti et al., 2005; Shi et al., 2005). Sec-
ond, it appears that speciﬁc B cell clones are enriched in the IgM+
memory cell population, residing in the spleen and the periph-
eral blood of individuals vaccinated against S. pneumonia (Weller
et al., 2004). Interestingly, IgM+ memory cells are not enriched
for broad reactivity against polysaccharide/bacterial antigens; B
cells with such speciﬁcities are negatively selected before entry
into the IgM+ memory compartment (Tsuiji et al., 2006). Instead,
these IgM+ memory B cells recognize speciﬁc individual bacter-
ial polysaccharides. These data, taken together, indicate that IgM+
memory B cells are important in speciﬁc T-independent responses
(Tsuiji et al., 2006).
There is also evidence that IgM+ memory cells are involved
in responses to TD antigens. In mice, many studies have demon-
strated that these memory cells can be generated in response to
TD antigen immunization and strongly support a role of IgM+
memory cells in the secondary response (White and Gray, 2000;
Soenawan et al., 2004). In humans, IgM secreting cells can be
generated in vitro upon stimulation of memory B cells from
individuals vaccinated against TD antigens such as hepatitis B
or in HIV-infected patients (Fondere et al., 2003; Tuaillon et al.,
2006). IgM memory cells are also detectable at a low frequency in
the memory cell pool weeks after inﬂuenza vaccination (Wram-
mert et al., 2008a). An elegant study furthering this idea used
mice transplanted with human B cells subsets and was able to
show that both IgM+ and switched memory cells can respond
to both TD and TI antigens (Moens et al., 2008). Interestingly,
in people with hepatitis-C associated mixed cryoglobulinemia,
there are clones of IgM memory cells that are massively expanded
and that use predominantly a single variable heavy chain gene,
VH1–69 (Charles et al., 2008, 2011).A recent based on global gene-
expression analysis and cellular assays in humans have proposed
to identify mechanisms that contribute to qualitative differences
between primary and secondary humoral responses (Good et al.,
2009). IgM+ and switched memory cells were compared; it was
observed that all memory B cells were found to have high expres-
sion of activation and pro-survival molecules such as B7, TNF
receptor, SLAM, Bcl2, and CD180 (Good et al., 2009). This is con-
sistent with the ability of the memory cells to respond quickly
and to form a pool of cells that persist after an immune response
(Good et al., 2009). Perhaps some of the most compelling evi-
dence for this idea comes from recent work, previously described,
indicating that IgM+ memory B cells are typically the cells to
reinitiate speciﬁc GC responses to antigen upon secondary chal-
lenge (Dogan et al., 2009; Pape et al., 2011). In order to resolve the
origin of these IgM+ memory cells, Seifert and Kuppers (2009)
analyzed the Bcl6 mutational level as a marker of GC experience.
The authors found that the IgM+ memory cells seem to arise
from the same GC reactions that are producing class-switched
memory B cells, but simply exiting earlier (Seifert and Kuppers,
2009). This data strongly points to the TD origin of IgM memory
cells.
These data indicate that IgM+ memory B cells have seem-
ingly multiple roles in an immune response. This effect appears to
depend greatly on the pathogen and the antigens that are exposed
to the immune system. More work must be done to tease apart
these two very different mechanisms for B cell response in, para-
doxically, what appears to be the same memory compartment.
The understanding of how these IgM+ B cell populations affect
an active immune response is in its infancy; the recent data is just
beginning to delineate how IgM+ B cell populations differ from
switched memory cells. It is possible that these studies will lead
to a much more structured and elegant picture of the immune
response that had previously not existed.
“FOOL ME ONCE. . .”: MEMORY RESPONSES TO INFECTIOUS
AGENTS AND VACCINES
In theory, memory B cell compartments to a pathogen or vacci-
nation should all be long-lived responses that can be called upon
after the initial challenge to counter secondary exposure to the
insult. However, instead of observing this type of response in all
cases; memory responses appear to be much more heterogeneous.
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This is likely due to diverse subsets that can be called upon during
an immune response, for better or worse.
PERSISTENT MEMORY RESPONSES
An important property of memory B cells is their ability to be
long-lived. The ability to survive in the peripheral blood after
activation allows the host to rapidly respond to a recurrent chal-
lenge in both kinetics and strength of response; as these cells have
already undergone afﬁnity maturation and are primed for quick
response (Engels et al., 2009). Remarkably, these long-lived mem-
ory B cells have the potential to be sustained in the peripheral
blood for decades following initial exposure to an immunological
insult. The generation of long-lived memory is the cornerstone
of modern vaccination. Arguably, the one of the greatest victo-
ries in the ﬁeld of vaccination was the eradication of the smallpox
virus in 1980 (Pennington, 2003). This feat was made possible by
the life-long immunity to the virus created by the vaccine. Stud-
ies analyzing the human response to the vaccine have shown that
childhood vaccination to the disease allows the patient to produce
smallpox speciﬁc B cells decades after the last appearance of the
disease in nature (Crotty et al., 2003, 2004; Hammarlund et al.,
2003). These studies demonstrate the persistence of a proper vac-
cine response even after the antigen has long since disappeared
from the earth (Crotty et al., 2003, 2004; Hammarlund et al.,
2003). Long-lived CD27+ memory B cell responses have also been
seen forVaricella Zoster virus and measles virus decades following
initial vaccination (Pinna et al., 2009).
It has been theorized that a persistent population of speciﬁc
memory B cells could lead to long-lived antibody titers through
the stimulation of these memory cells by polyclonal means, such
as CpG DNA and T cell cytokines; suggesting that a response
to a polyclonal stimulus can cause the polyclonal activation of
memory cells each with their own unique speciﬁcity, replenish-
ing the plasma cell populations sporadically over the course of a
lifetime without the requirement of speciﬁc antigenic stimulation
(Bernasconi et al., 2002). If this theory is true it would help to
dovetail the two ideas of long-lived memory B cells that do not
require antigenic stimulation, and plasma cells, which are pro-
ducing protective antibody titers over the course of a lifetime of
the host; pointing to the importance of driving not only plasma
cell formation but long-lived memory B cells for proper vaccine
efﬁcacy.
MEMORIES BLUR
Interestingly, other common vaccinations, such as the inﬂuenza
vaccination, have been seen to provide mixed results in the gen-
eration of long-term B cell memory. While the efﬁcacy of the
vaccine is dependent on the correct design of the yearly cocktail
and immunity to future strains is dependent on antigenic drift and
antigenic shift of the virus, CD27+ memory B cell persistence to
the virus seems to be variable depending on the vaccinating strain
(Ahmed et al., 2007; Pinna et al., 2009). Nonetheless, through
analysis of the variable gene repertoire we have noted that plas-
mablasts induced immediately after inﬂuenza vaccination (Wram-
mert et al., 2008a,b) or infection (Wrammert et al., 2011) appear to
be predominantly activated from pre-existing memory cells. The
antibody efﬁcacy was profoundly affected by this re-induction of
memory B cells in that the antigenically similar annual strains pre-
dominantly activated B cells to epitopes that were conserved but
not protective because selective pressure had induced these pro-
tective epitopes to drift (Wrammert et al., 2008a,b). Conversely,
infection with the highly divergent pandemic inﬂuenza strain in
2009 activated memory cells as well, but in this case they were
binding to conserved epitopes that were present because they are
critical for viral function or virulence, leading to a predominantly
protective response (Wrammert et al., 2011). These observations
demonstrate that by targeting particular memory cells for reacti-
vation, a better inﬂuenza vaccine might be developed that could
protect against most or all inﬂuenza strains.
Reports have indicated the discovery of inﬂuenza-speciﬁc
memory B cells to the 1918 pandemic ﬂu almost 100 years follow-
ing initial exposure to the virus (Yu et al., 2008). Conversely, work
on memory responses to inﬂuenza vaccination to A/Texas/36/91
Hemagglutinin (HA) were assayed in several patients from 1993
to 2006 and showed that levels of memory B cells speciﬁc to this
viral HA were ultimately lost by their ﬁnal time point (Pinna et al.,
2009). It is difﬁcult to say what might be attributing to this dif-
ference, it could be the variable conditions between live infection
and vaccination or it could be a condition of constant exposure to
slightly different strains each year.
Currently, work has been very limited in regard to the persis-
tence of inﬂuenza-speciﬁc memory, but there have been studies on
the elderly populations’ responses to novel 2009 pandemic H1N1
(Sasaki et al., 2011). Epidemiological data collected from the 2009
pandemic that indicated that the best protected population against
the pandemic inﬂuenza were born prior to 1957; being born after
this time point is associated with decreasing protection as births
approach present day (Fisman et al., 2009). In a recent study,
elderly populations were examined for their speciﬁc responses
to either their vaccinating antigen, 2009 seasonal H1N1, or to
the non-vaccinating antigen, novel 2009 pandemic H1N1 (Sasaki
et al., 2011). It was seen that both groups responded equally well
to the vaccinating antigen, but only the elderly patients showed
increased cross-reactivity to a non-vaccinating pandemic H1N1
strain (Sasaki et al., 2011). It is thought that these differences, both
epidemiologically and experimentally, derive from elderly popu-
lations’ increased exposure to inﬂuenza viruses over the course of
their lives, leading tomore robustmemory B cell response (Fisman
et al., 2009; Sasaki et al., 2011).
These recent studies provide insights intohowourbodiesmain-
tain memory B cell populations over the course of time in the
presence of constant antigen exposure, as in the case of inﬂuenza,
or when antigen is no longer present, as with the smallpox vaccine.
WANING IMMUNE RESPONSE TO VACCINES: THE IMPORTANCE OF
MEMORY B CELLS
Human licensed vaccines can be subdivided into two groups con-
cerning their ability to maintain speciﬁc antibody levels: vaccines
that elicit long-term, stable antibody production, like the small-
pox vaccine discussed earlier, and vaccines that do not. Designed
to combat the disease caused by the spore-forming bacteria Bacil-
lus anthracis, the Anthrax Vaccine Adsorbed (AVA or BioThrax;
Ivins and Welkos, 1988) is one of these vaccines. Unlike most suc-
cessful vaccines that require only one to three boosts to acquire
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FIGURE 1 | Specifically targeted memory B cell subset versus
non-targeted vaccination. (Above) A conceptual cartoon displaying the
beneﬁts of designing a vaccination with a particular B memory cell subset
targeted. The vaccine would be greatly dependent on the pathogen of interest
and route of infection. To prime the most effective B memory subset the type
of antigen and adjuvant must be rationally chosen based on the known
properties of the subset. By targeting a particular memory B cell subset in a
vaccine the localization, type and magnitude of antibody response, and the
maintenance of the memory B cell subset populations can be altered to
generate an effective antibody response upon subsequent exposure.
Conversely, non-speciﬁc memory B cell vaccine design can lead to the loss of
maintenance and/or establishment of important memory populations,
improper response localization, and ineffective antibody response. These
factors combined can lead to a loss of efﬁcacy in a vaccine.
permanent protective antibody titers, the anthrax vaccine must be
boosted repeatedly ﬁve times over the ﬁrst year and then annually
to maintain protective titers. As such, it is a good example of a
vaccine whose potency appears to wane with time. This vaccine
is composed predominantly of protective antigen (PA) that is a
key element of the anthrax toxin. Anti-PA IgG antibodies confer
protection to different animals challenged with B. anthracis (Ivins
et al., 1998; Pitt et al., 2001) and the efﬁcacy of AVA immunization
is based on quantity and neutralizing capacity of these anti-PA
antibodies (Crowe et al., 2010) that increase with successive or
recent boosts (Crowe et al., 2011). A study in people vaccinated
with the primary series of AVA (six ﬁrst doses) demonstrated that
the majority of the vaccinated individuals had developed anti-PA
IgG antibodies after two to three dosages,however, titers of anti-PA
antibody decreased over time (Pittman et al., 2006). The phenom-
ena of anti-PA antibody titer reduction over time has also been
observed in studies using rhesus macaques and mice (Ivins et al.,
1996; Tross and Klinman, 2008). Importantly, however, upon chal-
lenge with B. anthracis, a subset of animals exhibiting low or no
detectable amounts of PA-reactive sera butwere still able to survive
and produce PA-reactive Ig (Ivins et al., 1996; Tross and Klinman,
2008). Throughwork using aCpGadjuvant to attempt to boost the
vaccine response itwas seen that this effect derivedmainly from the
Bmemory compartment (Klinmanet al., 2006;Tross andKlinman,
2008). Unlike the unprotected group, the surviving animals had a
large populationof memoryB cells that expressedhigh afﬁnity,PA-
speciﬁc antibody (Tross and Klinman, 2008). What is interesting
is that these memory cells were only established in a subset of ani-
mals, begging the questions posed in Figure 1: how do you target
an appropriate memory response? Further,what was unique about
the response in protected versus susceptible animals? Because
CpG is more of a T-independent adjuvant, could targeting more
innate (B1-like) B cell populations induce this improved mem-
ory response to a less immunogenic vaccine? It is essential to learn
more about the B cell memory response and how it can be targeted
or for the establishment of new and more effective vaccines.
CONCLUSION
The discovery of B memory cell subsets has opened a door into
redeﬁning how we understand the establishment of long-term
immunological memory. By understanding the diversity of the
memoryB cell response,wewill be better equipped to answermany
outstanding questions in disease pathology. We have described
situations where both ineffective and effective immune memory
responses are generated to infection and vaccination. The acqui-
sition of a proper, effective immune response to a vaccination will
require careful planning during vaccine design to best take advan-
tage of the desirable properties of these subsets. To do this, more
research must be performed to ﬂesh out the environments that
create these subsets and understand their functional properties
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in vivo (Figure 1). It will be crucial to generate clinically relevant
means to reverse the effects of ineffective memory responses as
therapeutic treatments to ongoing, chronic infections. Much like
Jenner and Pasteur using the fundamental idea of immunologi-
cal memory to formulate strategies in prophylaxis to disease, this
powerful idea of the diversity in the memory B cell compartment
may make it possible to tear down age-old impediments that have
plagued the ﬁeld of vaccinology; leading to the design of novel and
effective treatments to the most stubborn diseases.
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